Skip to main
APYX

APYX Stock Forecast & Price Target

APYX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apyx Medical is an advanced energy company specializing in cosmetic and surgical products and technologies, including the Renuvion cosmetic technology, which offers controlled heat to achieve desired results. Their newly-launched Ayon body contouring system has shown strong early demand, positive surgeon feedback, and higher-than-expected pre-order activity, positioning them as a leader in the surgical skin tightening market. This, combined with their strategic rebranding, cost controls, and raised revenue outlook, makes Apyx Medical a promising investment opportunity with potential for long-term growth and improved profitability. However, potential risks include inconsistent commercial execution, competition, and regulatory delays.

Bears say

Apyx Medical is facing potential risks to its ratings and price target due to potential inconsistent commercial execution, slowdown in procedure volumes, competition, pricing pressure, negative clinical trial updates, regulatory delays, and supply chain challenges. Additionally, while the company is expanding into new markets and launching new products, there is uncertainty surrounding their success and ability to drive revenue growth. Furthermore, the company's high operating expenses may continue to impact its financial performance and results in the coming years.

APYX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apyx Medical Corp (APYX) Forecast

Analysts have given APYX a Strong Buy based on their latest research and market trends.

According to 4 analysts, APYX has a Strong Buy consensus rating as of May 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apyx Medical Corp (APYX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.